2020
DOI: 10.1111/dom.14085
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy and safety of lobeglitazone versus sitagliptin as an add‐on to metformin in patients with type 2 diabetes with two or more components of metabolic syndrome over 24 weeks

Abstract: We aimed to evaluate the efficacy and safety profile of lobeglitazone compared with sitagliptin as an add‐on to metformin in patients with type 2 diabetes as well as other components of metabolic syndrome. Patients inadequately controlled by metformin were randomly assigned to lobeglitazone (0.5 mg, n = 121) or sitagliptin (100 mg, n = 126) for 24 weeks. The mean changes in HbA1c of the lobeglitazone and sitagliptin groups were −0.79% and −0.86%, respectively; the between‐group difference was 0.08% (95% confid… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
6
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
5
1

Relationship

1
5

Authors

Journals

citations
Cited by 8 publications
(6 citation statements)
references
References 19 publications
(41 reference statements)
0
6
0
Order By: Relevance
“…When used as add-on therapy to metformin, mean weight gain was 0.92 kg in the lobeglitazone group, which did not differ significantly from that of the pioglitazone group (0.76 kg, P=0.569) [43]. Weight gain was greater with lobeglitazone than with sitagliptin when used as add-on therapy to metformin (mean difference, 1.34 kg; P<0.0001) [44]. Hypoglycemia was not reported in the monotherapy trial [41,42], while one subject (0.8%) in the lobeglitazone group versus three subjects (2.4%) in the pioglitazone group reported hypoglycemia when they were used as add-on therapy to metformin [43].…”
Section: Safety and Tolerabilitymentioning
confidence: 88%
See 4 more Smart Citations
“…When used as add-on therapy to metformin, mean weight gain was 0.92 kg in the lobeglitazone group, which did not differ significantly from that of the pioglitazone group (0.76 kg, P=0.569) [43]. Weight gain was greater with lobeglitazone than with sitagliptin when used as add-on therapy to metformin (mean difference, 1.34 kg; P<0.0001) [44]. Hypoglycemia was not reported in the monotherapy trial [41,42], while one subject (0.8%) in the lobeglitazone group versus three subjects (2.4%) in the pioglitazone group reported hypoglycemia when they were used as add-on therapy to metformin [43].…”
Section: Safety and Tolerabilitymentioning
confidence: 88%
“…In another randomized controlled study, 24 weeks of treatment with lobeglitazone ( n =121) as an add-on to metformin was non-inferior to sitagliptin add-on therapy ( n =126) with respect to glycemic efficacy (mean change in HbA1c –0.79% vs. –0.86%; difference, 0.08%; 95% CI, –0.14% to 0.30%) [ 44 ].…”
Section: Lobeglitazone Clinical Profilementioning
confidence: 99%
See 3 more Smart Citations